Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses
This is a pooled analysis of 2 studies registered at Clinicaltrials.gov: PATHWAY (NCT02054130) and NAVIGATOR (NCT03347279).
Authors
- Wojciech Feleszko (ORCID: https://orcid.org/0000-0001-6613-2012)
- Marco Caminati (ORCID: https://orcid.org/0000-0001-7383-1487)
- Sebastian Lennox Johnston (ORCID: https://orcid.org/0000-0003-3009-9200)
- Andrew Lindsley (ORCID: https://orcid.org/0000-0003-2670-704X)
- Cinzia Marchese (ORCID: https://orcid.org/0000-0002-9280-8917)
- Christopher S. Ambrose (ORCID: https://orcid.org/0000-0003-4175-7336)
- Deborah Clarke
- James E Gern
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Verona (IT)
- Amgen (United States) (US)
- University of Wisconsin–Madison (US)
- Medical University of Warsaw (PL)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Italy) (IT)
- AstraZeneca (United States) (US)
- Imperial College London (GB)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1016/j.anai.2025.09.015
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52